Results of the final analysis of the ABEL Phase II clinical trial


No votes yet
 
Related
ROVI REPORTS OPERATING REVENUE GROWTH OF 31% AND NET PROFIT GROWTH OF 58%   Operating revenue increased by 31% to 380.4...
3 min
27/07/2022
Madrid, 19th July 2022 The European Investment Bank (EIB) is providing Laboratorios Farmacéuticos Rovi (ROVI) with a new EUR 50 million...
4 min
19/07/2022
ROVI REPORTS OPERATING REVENUE GROWTH OF 57% AND NET PROFIT GROWTH OF 123% • Operating revenue increased by 57% to 205.6 million euros...
2 min
11/05/2022